Zoetis Inc (NYSE:ZTS) Director Willie M. Reed sold 3,205 shares of the business’s stock in a transaction dated Friday, November 30th. The shares were sold at an average price of $93.74, for a total value of $300,436.70. Following the completion of the transaction, the director now owns 566 shares in the company, valued at $53,056.84. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.
Shares of Zoetis stock traded down $0.30 during trading hours on Monday, hitting $93.57. The company’s stock had a trading volume of 1,923,200 shares, compared to its average volume of 2,517,697. The company has a quick ratio of 2.63, a current ratio of 4.06 and a debt-to-equity ratio of 3.04. The company has a market capitalization of $45.10 billion, a price-to-earnings ratio of 38.99, a PEG ratio of 1.85 and a beta of 0.99. Zoetis Inc has a 12-month low of $70.20 and a 12-month high of $96.57.
Zoetis (NYSE:ZTS) last posted its earnings results on Thursday, November 1st. The company reported $0.83 EPS for the quarter, topping analysts’ consensus estimates of $0.77 by $0.06. The company had revenue of $1.48 billion for the quarter, compared to the consensus estimate of $1.46 billion. Zoetis had a return on equity of 75.51% and a net margin of 20.35%. The firm’s revenue for the quarter was up 9.9% on a year-over-year basis. During the same period in the previous year, the business earned $0.65 earnings per share. On average, equities analysts expect that Zoetis Inc will post 3.11 earnings per share for the current year.
Several brokerages have recently commented on ZTS. Zacks Investment Research upgraded Zoetis from a “hold” rating to a “buy” rating and set a $100.00 price objective on the stock in a research report on Wednesday, October 17th. BMO Capital Markets boosted their price objective on Zoetis to $93.00 and gave the company a “neutral” rating in a research report on Monday, November 12th. They noted that the move was a valuation call. Stifel Nicolaus downgraded Zoetis from a “buy” rating to a “hold” rating and set a $95.00 price objective on the stock. in a research report on Tuesday, August 21st. They noted that the move was a valuation call. Argus boosted their price objective on Zoetis from $90.00 to $103.00 and gave the company a “buy” rating in a research report on Tuesday, August 14th. Finally, Cantor Fitzgerald restated a “buy” rating and issued a $98.00 price objective on shares of Zoetis in a research report on Monday, October 1st. Six research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus price target of $94.00.
Several large investors have recently bought and sold shares of ZTS. Banque Pictet & Cie SA lifted its position in shares of Zoetis by 5,516.1% in the second quarter. Banque Pictet & Cie SA now owns 1,679,617 shares of the company’s stock worth $143,087,000 after buying an additional 1,649,710 shares in the last quarter. Renaissance Technologies LLC lifted its position in shares of Zoetis by 206.5% in the third quarter. Renaissance Technologies LLC now owns 2,062,100 shares of the company’s stock worth $188,806,000 after buying an additional 1,389,300 shares in the last quarter. Janus Henderson Group PLC lifted its position in shares of Zoetis by 22.3% in the second quarter. Janus Henderson Group PLC now owns 5,410,040 shares of the company’s stock worth $460,890,000 after buying an additional 985,586 shares in the last quarter. Deutsche Bank AG lifted its position in shares of Zoetis by 55.5% in the third quarter. Deutsche Bank AG now owns 2,677,762 shares of the company’s stock worth $245,169,000 after buying an additional 955,954 shares in the last quarter. Finally, AQR Capital Management LLC lifted its position in shares of Zoetis by 51.9% in the third quarter. AQR Capital Management LLC now owns 2,629,436 shares of the company’s stock worth $240,751,000 after buying an additional 898,015 shares in the last quarter. Institutional investors own 89.94% of the company’s stock.
Zoetis, Inc discovers, develops and manufactures a portfolio of animal health medicines and vaccines. Its products are complemented by diagnostic products, genetic tests, bio devices and services. These are designed to meet the needs of veterinarians and the livestock farmers and companion animal. The firm provides its services though five categories namely, anti-invectives, vaccines, parasitic ides, medicated feed additives, and other pharmaceuticals.
Featured Article: Tariff
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.